SGLT‐2 Inhibitors in Heart Failure: Current Management, Unmet Needs, and Therapeutic Prospects
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
SGLT‐2 Inhibitors in Heart Failure: Current Management, Unmet Needs, and Therapeutic Prospects
Authors
Keywords
-
Journal
Journal of the American Heart Association
Volume 8, Issue 20, Pages -
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2019-10-12
DOI
10.1161/jaha.119.013389
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA
- (2019) Darren K. McGuire et al. CIRCULATION
- Trends in survival after a diagnosis of heart failure in the United Kingdom 2000-2017: population based cohort study
- (2019) Clare J Taylor et al. BMJ-British Medical Journal
- Effects of Canagliflozin on Heart Failure Outcomes Associated with Preserved and Reduced Ejection Fraction in Type 2 Diabetes: Results from the CANVAS Program
- (2019) Gemma A. Figtree et al. CIRCULATION
- Dapagliflozin and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Prior Myocardial Infarction: A Sub-analysis From DECLARE TIMI-58 Trial
- (2019) Remo H. M. Furtado et al. CIRCULATION
- Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus
- (2019) Eri T. Kato et al. CIRCULATION
- Sodium–glucose co‐transporter 2 inhibition with empagliflozin improves cardiac function in non‐diabetic rats with left ventricular dysfunction after myocardial infarction
- (2019) Salva R. Yurista et al. EUROPEAN JOURNAL OF HEART FAILURE
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care
- (2019) Elisabetta Patorno et al. CIRCULATION
- SGLT2 Inhibition with Empagliflozin Increases Circulating Provascular Progenitor Cells in People with Type 2 Diabetes Mellitus
- (2019) David A. Hess et al. Cell Metabolism
- Inter-organ Communication Pathway Manifested by Non-physiological Stress to the Kidney in Type II Diabetic Patients -Why Are Diabetic Patients Prone to Develop Heart Failure?
- (2019) Motoaki Sano INTERNAL MEDICINE
- Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)
- (2018) Karin Rådholm et al. CIRCULATION
- Non-cardiac comorbidities in heart failure with reduced, mid-range and preserved ejection fraction
- (2018) Koen W. Streng et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission
- (2018) Hao Zhou et al. Redox Biology
- Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study
- (2018) Tiew-Hwa K Teng et al. Lancet Global Health
- SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practice
- (2018) John Wilding et al. Diabetes Therapy
- Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure
- (2018) Fumitaka Soga et al. Cardiovascular Diabetology
- SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
- (2018) Thomas A Zelniker et al. LANCET
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study
- (2018) Peter Ueda et al. BMJ-British Medical Journal
- P4903Empagliflozin reduces heart failure irrespective of control of blood pressure, low density lipoprotein cholesterol and HbA1c
- (2017) D. Fitchett et al. EUROPEAN HEART JOURNAL
- Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study
- (2017) W. Ouwerkerk et al. EUROPEAN HEART JOURNAL
- Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial
- (2017) David Fitchett et al. EUROPEAN HEART JOURNAL
- Organ dysfunction, injury and failure in acute heart failure: from pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)
- (2017) Veli-Pekka Harjola et al. EUROPEAN JOURNAL OF HEART FAILURE
- Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts
- (2017) Tsung-Ming Lee et al. FREE RADICAL BIOLOGY AND MEDICINE
- Heart Failure With Preserved, Borderline, and Reduced Ejection Fraction
- (2017) Kevin S. Shah et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
- (2017) Theo Vos et al. LANCET
- Effect of empagliflozin on cardiac biomarkers in a zebrafish model of heart failure: clues to the EMPA-REG OUTCOME trial?
- (2017) Xingjuan Shi et al. MOLECULAR AND CELLULAR BIOCHEMISTRY
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Metabolodiuretic Promise of Sodium-Dependent Glucose Cotransporter 2 Inhibition
- (2017) Subodh Verma et al. JAMA Cardiology
- Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure
- (2017) Milton Packer et al. JAMA Cardiology
- Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events
- (2017) Kenneth W. Mahaffey et al. CIRCULATION
- Glucagon and heart in type 2 diabetes: new perspectives
- (2016) Antonio Ceriello et al. Cardiovascular Diabetology
- Cardiac Fibrosis
- (2016) Joshua G. Travers et al. CIRCULATION RESEARCH
- Effect of Empagliflozin on Left Ventricular Mass and Diastolic Function in Individuals With Diabetes: An Important Clue to the EMPA-REG OUTCOME Trial?
- (2016) Subodh Verma et al. DIABETES CARE
- CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis
- (2016) Ele Ferrannini et al. DIABETES CARE
- Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits
- (2016) Antonius Baartscheer et al. DIABETOLOGIA
- Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME®trial
- (2016) David Fitchett et al. EUROPEAN HEART JOURNAL
- 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
- (2016) Piotr Ponikowski et al. EUROPEAN HEART JOURNAL
- Heart failure outcomes in clinical trials of glucose-lowering agents in patients with diabetes
- (2016) David H. Fitchett et al. EUROPEAN JOURNAL OF HEART FAILURE
- Impact of Diabetes Mellitus on Hospitalization for Heart Failure, Cardiovascular Events, and DeathCLINICAL PERSPECTIVE
- (2015) Matthew A. Cavender et al. CIRCULATION
- Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes
- (2015) R. Chilton et al. DIABETES OBESITY & METABOLISM
- What does the lay public know about heart failure? Findings from the Heart Failure Awareness Day Initiative
- (2015) Stefan Störk et al. EUROPEAN JOURNAL OF HEART FAILURE
- Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion
- (2015) Caroline Bonner et al. NATURE MEDICINE
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Public health General public awareness of heart failure: results of questionnaire survey during Heart Failure Awareness Day 2011
- (2014) Mitja Lainscak et al. Archives of Medical Science
- Diabetes Mellitus, Prediabetes, and Incidence of Subclinical Myocardial Damage
- (2014) Elizabeth Selvin et al. CIRCULATION
- Noncardiac Comorbidities in Heart Failure With Reduced Versus Preserved Ejection Fraction
- (2014) Robert J. Mentz et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Spironolactone for Heart Failure with Preserved Ejection Fraction
- (2014) Bertram Pitt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure
- (2014) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Endothelial dysfunction — A major mediator of diabetic vascular disease
- (2013) Cristina M. Sena et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- 2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary
- (2013) Clyde W. Yancy et al. CIRCULATION
- Forecasting the Impact of Heart Failure in the United States
- (2013) Paul A. Heidenreich et al. Circulation-Heart Failure
- Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes
- (2013) T. Heise et al. DIABETES OBESITY & METABOLISM
- EURObservationalResearch Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot)
- (2013) Aldo P. Maggioni et al. EUROPEAN JOURNAL OF HEART FAILURE
- Natriuretic Peptide–Based Screening and Collaborative Care for Heart Failure
- (2013) Mark Ledwidge et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- PONTIAC (NT-proBNP Selected PreventiOn of cardiac eveNts in a populaTion of dIabetic patients without A history of Cardiac disease)
- (2013) Martin Huelsmann et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Impact of Noncardiac Comorbidities on Morbidity and Mortality in a Predominantly Male Population With Heart Failure and Preserved Versus Reduced Ejection Fraction
- (2012) Sameer Ather et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- 2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults
- (2009) et al. CIRCULATION
- Cardiorenal Syndrome in Acute Decompensated Heart Failure
- (2009) M. Sarraf et al. Clinical Journal of the American Society of Nephrology
- Heart Failure Incidence and Survival (from the Atherosclerosis Risk in Communities Study)
- (2008) Laura R. Loehr et al. AMERICAN JOURNAL OF CARDIOLOGY
- Chronic inhibition of the Na+/H+- exchanger causes regression of hypertrophy, heart failure, and ionic and electrophysiological remodelling
- (2008) A Baartscheer et al. BRITISH JOURNAL OF PHARMACOLOGY
- Awareness and perception of heart failure among European cardiologists, internists, geriatricians, and primary care physicians
- (2008) W. J. Remme et al. EUROPEAN HEART JOURNAL
- Timing of Immunoreactive B-Type Natriuretic Peptide Levels and Treatment Delay in Acute Decompensated Heart Failure
- (2008) Alan S. Maisel et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Cardiorenal Syndrome
- (2008) Claudio Ronco et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial
- (2008) GISSI-HF investigators LANCET
- Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction
- (2008) Barry M. Massie et al. NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now